71 filings
Page 3 of 4
6-K
2rsm0vh
13 Dec 21
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
6:10am
6-K
6ypdk7d83f7v353 h1lj
30 Nov 21
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
6:10am
6-K
lixmnq64wa rc
16 Nov 21
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19
6:10am
6-K
5rcmbc2oo
28 Oct 21
Current report (foreign)
6:11am
6-K
wk34njck7wgzmjc74ozm
26 Aug 21
Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
6:10am
6-K
qxqcsid
9 Aug 21
Molecular Partners to Regain Global Rights to Abicipar
6:05am
6-K
hzybsasxbqzwt2
8 Jul 21
Current report (foreign)
9:17am
424B4
hmots
16 Jun 21
Prospectus supplement with pricing info
5:23pm
EFFECT
38ceo5 0oveif0
16 Jun 21
Notice of effectiveness
12:15am
EFFECT
pjkn fmrjy
16 Jun 21
Notice of effectiveness
12:15am
SEC STAFF
26sv4wablkt8lt5be3d
16 Jun 21
SEC staff action: Order
12:00am
CERT
07mfbizm
15 Jun 21
Certification of approval for exchange listing
10:17am
F-1/A
ussnv5tgbjue18s
14 Jun 21
Registration statement (foreign) (amended)
9:08am
FWP
2xmtowk ax
14 Jun 21
Free writing prospectus
9:06am
8-A12B
r5bjgpb16wj
11 Jun 21
Registration of securities on exchange
4:03pm
CORRESP
9wmim 8uje0
11 Jun 21
Correspondence with SEC
12:00am
CORRESP
bonvw 2liqkq6zgea1
11 Jun 21
Correspondence with SEC
12:00am
F-1/A
jix7ju5vg0bldwaq
10 Jun 21
Registration statement (foreign) (amended)
5:04pm
CORRESP
ck759pfhqfu 6r2b
10 Jun 21
Correspondence with SEC
12:00am
F-6
zzsw6nx
9 Jun 21
Registration for ADRs (foreign)
12:01pm